Daily Endocrinology Research Analysis
Analyzed 96 papers and selected 3 impactful papers.
Summary
Three studies stand out in endocrinology and metabolism. A phase 2 randomized trial shows the dual glucagon/GLP-1 receptor agonist mazdutide 9 mg induces ~13% weight loss in 24 weeks with cardiometabolic benefits. A systematic review/meta-analysis in children under 7 years with type 1 diabetes demonstrates automated insulin delivery improves time-in-range by ~10% with good safety, and a nationwide cohort of over 2 million people with type 2 diabetes links waist-to-height ratio ≥0.5 to higher cardiovascular risk and mortality, even without abdominal obesity.
Research Themes
- Anti-obesity pharmacotherapy and dual-receptor agonists
- Automated insulin delivery in early childhood type 1 diabetes
- Anthropometric risk markers (waist-to-height ratio) for cardiovascular outcomes in T2D
Selected Articles
1. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m
In a double-blind, placebo-controlled phase 2 RCT of adults with obesity (n=80), once-weekly mazdutide 9 mg produced a mean 12.78% weight loss over 24 weeks versus a 1.80% gain with placebo, a -14.58% treatment difference. Cardiometabolic risk factors improved, and gastrointestinal adverse events were common but generally mild-to-moderate.
Impact: This trial demonstrates substantial, clinically meaningful weight loss with a novel dual glucagon/GLP-1 receptor agonist, alongside improvements in cardiometabolic risk—signaling a potential step-change in anti-obesity pharmacotherapy.
Clinical Implications: If confirmed in phase 3, mazdutide could expand effective pharmacologic options for obesity, achieving double-digit weight loss. Clinicians should monitor and manage gastrointestinal adverse events and consider patient selection and titration strategies.
Key Findings
- At 24 weeks, mean weight change was -12.78% with mazdutide 9 mg vs +1.80% with placebo (treatment difference -14.58%; p<0.0001).
- 81.7% of participants on mazdutide achieved ≥5% weight loss; none did so with placebo.
- Mazdutide improved multiple cardiometabolic risk factors compared with placebo.
- Gastrointestinal adverse events (nausea 50.0%, diarrhea 38.3%, vomiting 36.7%) were most common and mainly mild-to-moderate.
Methodological Strengths
- Randomized, double-blind, placebo-controlled phase 2 design with clear primary endpoint (percentage weight change).
- Clinically meaningful effect size with consistent improvement across cardiometabolic parameters.
Limitations
- Modest sample size (n=80) and 24-week duration limit long-term efficacy/safety assessment.
- Single-country population (Chinese adults) may affect generalizability; study sponsored by manufacturer.
Future Directions: Phase 3 trials should evaluate long-term efficacy/safety, cardiovascular and hepatic outcomes, dose-titration strategies, and comparative effectiveness versus GLP-1/GIP co-agonists and tirzepatide-like agents.
BACKGROUND: Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity. METHODS: In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m FINDINGS: Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20). At week 24, the mean percentage change in weight from baseline was -12.78% with mazdutide 9 mg and 1.80% with placebo (treatment difference: -14.58% [95% confidence interval (CI) -18.00, -11.16], p < 0.0001). Weight reduction ≥5% was achieved by 81.7% of participants with mazdutide after 24-week treatment, while no participants with placebo achieved this threshold. Mazdutide treatment was associated with greater improvements in cardiometabolic risk factors vs. placebo. The most common adverse events included nausea (50.0% with mazdutide vs. 0% with placebo), diarrhea (38.3% vs. 10.0%), and vomiting (36.7% vs. 10.0%), predominantly mild to moderate in severity. CONCLUSIONS: Mazdutide 9 mg was safe and led to substantial weight reductions in Chinese adults with a BMI ≥ 30kg/m FUNDING: This study was sponsored by Innovent Biologics.
2. Automated Insulin Delivery in Young Children with Type 1 Diabetes: A Systematic Review and Meta-Analysis.
Across 30 studies including 1,155 children under 7 years, AID increased time-in-range by 9.88% (~2.37 h/day), with consistent daytime and especially overnight benefits and low rates of severe hypoglycemia and DKA. Improvements were broadly similar across commercial and open-source systems.
Impact: This synthesis provides the strongest to-date evidence that AID benefits very young children, a population historically underrepresented in trials, informing practice, reimbursement, and pediatric guideline updates.
Clinical Implications: Supports adoption of AID in children under 7 to improve TIR without increasing hypoglycemia, with emphasis on overnight control. Implementation should include caregiver training, device access, and follow-up to optimize settings.
Key Findings
- AID increased time-in-range by 9.88% (95% CI 9.14–10.62), equivalent to ~2.37 hours/day; heterogeneity was low (I2=8%).
- Daytime TIR improved by 6.88% and overnight TIR by 16.85%, indicating strong nocturnal benefit.
- Benefits were consistent across systems (MiniMed 670G/780G, CamAPS FX, Control-IQ, Omnipod 5, open-source).
- Severe hypoglycemia and diabetic ketoacidosis events were infrequent; HbA1c reductions were modest.
Methodological Strengths
- Comprehensive multi-database search with predefined primary endpoint (TIR) and random-effects meta-analysis.
- Large aggregate sample including nine RCTs; low heterogeneity for the primary outcome and device-stratified analyses.
Limitations
- Inclusion of non-randomized designs and English-only studies may introduce bias.
- Heterogeneity in device algorithms, settings, and follow-up durations across studies.
Future Directions: Head-to-head RCTs in very young children comparing AID systems, standardized outcome reporting, and long-term neurocognitive and quality-of-life endpoints are needed.
BACKGROUND: Automated insulin delivery (AID) in young children (<7 years) with type 1 diabetes has not yet been systematically evaluated. MATERIALS AND METHODS: Web of Science, PubMed, Scopus, CENTRAL, and ClinicalTrials.gov were searched from inception to December 9, 2025. Studies reporting glycemic outcomes in children younger than 7 years were included in this meta-analysis. Studies not published in English were excluded. The primary outcome was the change in time-in-range (TIR; 70-180 mg/dL). Pooled estimates were calculated using random-effects models and expressed as mean changes (MCs) with 95% confidence intervals (CIs). RESULTS: This study included 30 studies (9 randomized controlled trials, 7 single-arm studies, and 14 cohort studies) involving 1,155 young children. AID systems were associated with a significant increase in TIR (MC, 9.88% [95% CI 9.14 to 10.62], I2 = 8%, p < 0.0001, moderate certainty), equivalent to 2.37 h/day. Favorable improvement was also observed during the daytime (MC, 6.88% [95% CI 5.70 to 8.07]) and overnight (MC, 16.85% [95% CI 13.48 to 20.22]). TIR improvements were comparable across devices: MiniMed 670G (9.65%), MiniMed 780G (10.04%), CamAPS FX (10.58%), Control-IQ (9.51%), Omnipod 5 (10.25%), and Open Source (6.77%). AID use was also associated with reduced hyperglycemia exposure and modest reductions in glycated hemoglobin, without significant changes in hypoglycemia exposure. Episodes of severe hypoglycemia and diabetic ketoacidosis were infrequent. CONCLUSION: This systematic review with meta-analysis revealed that AID systems have greater benefits for improving glycemic outcomes and have good safety profiles in young children with type 1 diabetes.
3. Waist-to-Height Ratio and the Risk of Cardiovascular Outcomes and Mortality in Type 2 Diabetes With and Without Abdominal Obesity.
In over 2 million adults with T2D, WHtR ≥0.5 was associated with higher risks of myocardial infarction, stroke, and mortality, with a U-shaped mortality relationship overall. Findings held even in those without abdominal obesity, supporting WHtR as a simple, informative risk marker beyond waist circumference.
Impact: The sheer scale and robust modeling establish WHtR as a practical, independent cardiometabolic risk stratifier in T2D, including patients without traditional abdominal obesity.
Clinical Implications: Routine WHtR measurement (threshold ≥0.5) can refine cardiovascular risk assessment in T2D beyond waist circumference, prompting earlier lifestyle and pharmacologic interventions, especially in younger or newly diagnosed individuals.
Key Findings
- WHtR showed positive, graded associations with incident myocardial infarction and stroke, and a U-shaped association with all-cause mortality.
- Patients with abdominal obesity and WHtR ≥0.5 had increased risks of MI (HR 1.12), stroke (HR 1.18), and mortality (HR 1.20).
- Even without abdominal obesity, WHtR ≥0.5 was linked to higher cardiovascular risks.
- Associations were stronger in younger adults and those with new-onset T2D (for CV events), and in long-standing T2D for mortality.
Methodological Strengths
- Exceptionally large, population-based cohort with national coverage and robust multivariable Cox modeling.
- Dose-response assessment via restricted cubic spline and stratification by abdominal obesity.
Limitations
- Observational design limits causal inference; residual confounding is possible.
- Single-country cohort may limit generalizability; anthropometry measured at baseline only.
Future Directions: Evaluate WHtR-guided interventions in T2D and validate thresholds across diverse populations; integrate WHtR into risk calculators and test clinical impact on outcomes.
AIM: Waist-to-height ratio (WHtR) has been suggested as a superior marker of cardiometabolic risk compared to waist circumference (WC), but evidence in type 2 diabetes mellitus (T2DM) remains limited. MATERIALS AND METHODS: A population-based cohort of 2 076 104 patients with T2DM who underwent the Korean national health checkup between 2015 and 2016 were followed until 2022. Multivariable Cox proportional hazards regression was performed to analyse the association between WHtR and the risk of incident myocardial infarction, stroke and mortality. Restricted cubic spline analyses were performed to evaluate continuous dose-response relationships, with additional stratification by abdominal obesity. RESULTS: During follow-up, 125 493 deaths (6.0%), 56 280 myocardial infarctions (2.7%) and 62 938 strokes (3.0%) occurred. WHtR showed increasing association with the risk of myocardial infarction and stroke, and a U-shaped association with all-cause mortality. Individuals with both abdominal obesity and WHtR ≥ 0.5 had higher risks of myocardial infarction (HR 1.12, 95% CI 1.07-1.17), stroke (HR 1.18, 95% CI 1.15-1.21) and mortality (HR 1.20, 95% CI 1.16-1.25). In those without abdominal obesity, WHtR ≥ 0.5 was also associated with increased cardiovascular risks but slightly lower mortality. In contrast, those with abdominal obesity but normal WHtR had no significantly increased risks for any outcomes. The associations were stronger in younger adults and individuals with new-onset T2DM for cardiovascular outcomes, and in those with long-standing T2DM for mortality. CONCLUSIONS: WHtR was independently associated with cardiovascular outcomes and mortality in individuals with T2DM, including those without abdominal obesity. This simple measurement may provide additional information beyond WC for evaluating cardiometabolic risk in this population.